Merck is discussing with global health authorities the potential use of its COVID-19 antiviral pill, molnupiravir, as an Ebola treatment. This discussion targets the widening outbreak in the Democratic Republic of Congo (DRC).
The current Ebola outbreak has reportedly infected 1,100 people and caused 42 deaths. This particular strain of the virus, called Bundibugyo, currently lacks approved vaccines or treatments. Molnupiravir, initially approved for emergency use against mild-to-moderate COVID-19, has shown some effectiveness against Ebola in animal studies.
This initiative could significantly impact global health strategies and pharmaceutical market dynamics in Africa. The lack of specific treatments for rare Ebola strains like Bundibugyo presents a critical public health challenge. Repurposing an existing drug could offer a faster and more accessible solution during an escalating crisis. The economic implications include potential procurement contracts and research funding reallocations.
Eliav Barr, Chief Medical Officer at Merck Research Laboratories, confirmed these discussions. He stated, "Molnupiravir is a non-specific RNA virus drug. We're thinking about how we could use that." Barr added that Merck is in extensive talks with various parties regarding this possibility.
The potential adoption of molnupiravir could influence emergency health spending and international aid efforts in the DRC and surrounding regions, including Uganda, where cases have also appeared. Decision-makers will weigh the clinical evidence from ongoing studies and potential approval timelines. Pharmaceutical markets will also observe Merck's progress in expanding its drug's applications beyond COVID-19. Ghana, a regional neighbour, has activated national emergency protocols to assess its Ebola preparedness, highlighting the wider regional concern.
Merck also manufactures an Ebola vaccine, Ervebo, effective against the more common Zaire strain. Barr suggested the technology behind Ervebo might be adapted for a new vaccine targeting the Bundibugyo strain. He described the growing outbreak as "very frightening." Merck maintains HIV research sites in Uganda, bordering the DRC, underscoring their proximity to the crisis. Uganda has already reported nine confirmed Ebola cases and one death, leading to heightened vigilance across the East African region.
This development comes as global health organizations, including the World Health Organization (WHO), intensify efforts to contain the outbreak. The economic burden of managing such an epidemic, including healthcare costs, supply chain disruptions, and potential trade restrictions, can be substantial. A viable treatment option could alleviate some of these pressures.